Companies Dominating the Fatty Acid Oxidation Disorder Landscape
- Ultragenyx Pharmaceutical Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Recordati Rare Diseases Inc.
- Retrophin, Inc.
- Amicus Therapeutics, Inc.
- Aeglea BioTherapeutics, Inc.
- Zogenix, Inc.
- Homology Medicines, Inc.
- Censa Pharmaceuticals Inc.
- Takeda Pharmaceutical Company Limited
- Regenxbio Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of fatty acid oxidation disorder is estimated at USD 11.54 billion.
The fatty acid oxidation disorder market size was over USD 10.82 billion in 2024 and is anticipated to cross USD 28.73 billion by 2037, witnessing more than 7.8% CAGR during the forecast period i.e., between 2025-2037. Increasing demand for healthcare sector will fuel the market growth.
Asia Pacific industry is expected to account for largest revenue share of 38% by 2037, impelled by multifaceted approach involving increased awareness in the region.
The major players in the market are Ultragenyx Pharmaceutical Inc., Recordati Rare Diseases Inc., Retrophin, Inc., Amicus Therapeutics, Inc., Aeglea BioTherapeutics, Inc., Zogenix, Inc., and others.
